Recce Pharmaceuticals (ASX:RCE) Presentation, FNN Investor Event, June 2018, Sydney

Company Presentations

Recce Pharmaceuticals Limited (ASX:RCE) Executive Director, James Graham presents on the company's lead prodct RECCE 327 for use in targeting antibiotic-resistant bacteria, its US FDA approval pathway and a Phase 1 clinical trial.

Key points:

- A whole new class of antibiotic
- RECCE 327 - a broad spectrum antibiotic for sepsis
- Qualified Infectious Disease Product - 10 Years market exclusivity (post approval)
- Patented manufacturing to Phase I and II volumes
- In discussion with US Food and Drug Administration
- Publicly listed on the ASX 2016

For more, watch the Executive Director, James Graham present.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.